Efficacy of Palivizumab Immunoprophylaxis for Reducing Severe RSV Outcomes in Children with Immunodeficiencies: A Systematic Review.

Frederic ReicherzBahaa Abu-RayaOmolabake AkinseyeShahrad Rod RassekhMatthew O WiensPascal M Lavoie

Published in: Journal of the Pediatric Infectious Diseases Society (2024)

The evidence supporting the use of palivizumab for prevention of severe RSV disease in immunocompromised children remains extremely limited and appears insufficient to justify prioritizing this intervention as the current standard of care over alternative interventions.

Keyphrases

respiratory syncytial virus
young adults
randomized controlled trial
early onset
healthcare
palliative care
respiratory tract
physical activity
intensive care unit
metabolic syndrome
drug induced